TIDMHIK 
 
RNS Number : 8943H 
Hikma Pharmaceuticals Plc 
01 March 2010 
 

 
 
 
 
 
 
  Hikma will release its 2009 preliminary results on Wednesday, March 17, 2010 
 
LONDON, 1 March 2010 - Hikma Pharmaceuticals PLC ("Hikma") (LSE: HIK) (Nasdaq 
Dubai: HIK), the fast growing multinational pharmaceutical Group, will release 
its 2009 preliminary results on Wednesday, 17 March 2010. The company will host 
a presentation for analysts at 9am and a live webcast of the presentation will 
be available on Hikma's website. www.hikma.com 
 
 
=- ENDS -- 
 
 
Enquiries: 
 
Hikma Pharmaceuticals PLC 
Said Darwazah, Chief Executive Officer 
Bassam Kanaan, Chief Financial Officer 
Susan Ringdal, Investor Relations Director                       Tel: +44 (0)20 
7399 2760 
 
Brunswick Group 
Jon Coles / Justine McIlroy                                             Tel: +44 
(0)20 7404 5959 
 
 
Hikma Pharmaceuticals PLC is a fast growing multinational group focused on 
developing, manufacturing and marketing a broad range of both branded and 
non-branded generic and in-licensed products.  Hikma's operations are conducted 
through three businesses: "Branded", "Injectables" and "Generics" based 
principally in the Middle East and North Africa ("MENA") region, where it is a 
market leader, the United States and Europe.  In 2008, Hikma achieved revenues 
of $581 million and profit attributable to shareholders of $57 million.  For 
news and other information, please visit www.hikma.com. 
 
 
 
 
 
 
 
 
 
This information is provided by RNS 
            The company news service from the London Stock Exchange 
   END 
 
 NORDMGGFNMVGGZM
Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From Jun 2024 to Jul 2024 Click Here for more Hikma Pharmaceuticals Charts.
Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From Jul 2023 to Jul 2024 Click Here for more Hikma Pharmaceuticals Charts.